Samuel Rae | TalkMarkets | Page 1

Samuel Rae

Currency Trader, Author/Journalist
Samuel is a currency trader, retail investor, author and contributor to a number of the leading trading market publications, including Futures Magazine, FX Trader Magazine, Master Investor and Spreadbet Magazine. His book, more
Following: 22 Followers: 2730

All Contributions

Latest Posts
1 to 16 of 17 Posts
1 2 >>>
Here's A Look At The Drug That Underpins The Latest Aptose Biosciences Inc. Designation
Friday, January 5, 2018 11:44 AM EDT
Aptose Biosciences Inc. picked up Orphan Designation for an early stage development asset on Dec 26, 2017. Here's a look at what that means.
In this article: APTO
Read
Otonomy Just Did Something That's Almost Never Seen In Biotech
Friday, November 10, 2017 10:46 PM EDT
Here's a look at the latest Otonomy development and why it's so unusual and, at the same time, potentially game-changing for the company.
In this article: OTIC
Read
Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Wednesday, October 11, 2017 9:36 AM EDT
Here's a look at Sarepta's latest data and where it fits into the company's Duchenne muscular dystrophy (DMD) portfolio. From a trader's perspective, Sarepta looks like it could be a strong pick heading into early 2018 and beyond.
In this article: SRPT
Read
AstraZeneca And Takeda Pharmaceutical Company Limited Parkinson's Collaboration
Thursday, August 31, 2017 12:48 PM EDT
AstraZeneca announced that it has put together a deal with Takeda Pharmaceutical Company Limited that will see the two collaborate on the development of a brand-new Parkinson's disease asset.
In this article: AZN, TKPYY Also: RHHBY, PRTA
Read
Here Are Two Exposures To The Coming Copper Boom With Near Term Catalysts
Friday, August 25, 2017 8:21 PM EDT
Here's a look at two copper stocks that could be set to gain on both near term catalysts and longer term industry trends.
In this article: USAU, OZMLY, OZL Also: BHP
Read
Here's What Markets Have Missed By Overlooking The VBI Vaccines CMV News
Tuesday, August 15, 2017 11:13 AM EDT
Here's a look at the latest data from VBI Vaccines' CMV trial with a discussion of what to look out for next from the program.
In this article: VBIV
Read
What The Latest Conference Call Says About Wirecard's Efforts In The Payments Space
Friday, May 26, 2017 11:32 AM EDT
Here's a look at why Wirecard AG could be a smart pick in a busy industry, and an analysis of the company's latest earnings call to support the thesis.
In this article: WRCDF
Read
An Update On VBI Vaccines Inc: What's Happened And What It Means
Thursday, April 20, 2017 6:06 PM EDT
Here's an update to my recent coverage of vaccine-focused biotechnology play VBI Vaccines. What's changed since the last time I looked at the company, and how does it affect shareholders going forward?
In this article: VBIV Also: DVAX
Read
Breaking Down VBI Vaccines' Pipeline: Descriptions And Catalysts
Saturday, February 18, 2017 1:12 PM EDT
Here's a look at VBI Vaccines' (VBIV) pipeline and the events that should drive value for the company going forward; with caveats.
In this article: GSK, SNY, VBIV Also: OPK
Read
Blake Insomnia Therapeutics Inc : A Beta Blocker As Sleeping Pill?
Friday, January 13, 2017 4:04 PM EDT
A critical look at Blake Insmonia Therapeutics, which is trying to overcome the problems associated with standard of care sleeping pills using beta blockers as an active ingredient, against a backdrop of email promotion.
In this article: BKIT
Read
While Markets Focus On Apple And Magic Leap, Vuzix Corporation Is Quietly Building A Wearable Tech Empire
Friday, December 2, 2016 12:37 PM EDT
A look at the development landscape in smart glasses, and a company that has successfully commercialized the technology where others have struggled.
In this article: VUZI Also: AAPL, GOOGL
Read
Biotech Is Hot But Here’s One Markets Just Missed: MabVax Therapeutics Holdings
Thursday, December 1, 2016 6:29 PM EDT
Here's a look at the latest development in MabVax, and why moving from stage one to stage two in the company's lead trial is so important.
In this article: MBVX Also: PZRX
Read
Portola Pharmaceuticals Inc. Is A Stock To Watch With Caution Ahead Of PDUFA
Thursday, July 7, 2016 1:14 PM EDT
Portola Pharmaceuticals Inc (PTLA) could recover its year to date losses come its August PDUFA. Here's both sides of the story.
In this article: PTLA
Read
Three Exposures To Small Cap Gold With Varying Risk Profiles
Tuesday, May 24, 2016 12:12 PM EDT
Here's a look at how investors can gain exposure to the small cap gold space, with an option for individuals with varying levels of risk tolerance.
In this article: GLDX, PLGTF, GDXJ, PSNP Also: FNV, NEM, SLW
Read
DraftDay: The Only Publicly Traded Option In A Multi Billion Dollar US Industry
Tuesday, May 17, 2016 11:46 PM EDT
Here is a look at DraftDay, Inc., which is the only direct, publicly traded exposures to the fantasy sports industry in the US.
In this article: KHC, CMCSA, GOOGL, FOX, DDAY
Read
A Market Opportunity Not Yet Priced Into Aerie Pharmaceuticals, Inc.
Monday, September 21, 2015 1:33 PM EDT
A detailed look at why a redesigned trial could be the key to a discounted exposure to some upsides in Aerie Pharma.
In this article: AERI
Read
1 to 16 of 17 Posts
1 2 >>>